Description
HYZENTRA 20ML VIALS/ "CRITICAL FUNCTIONS"
First action · last action
2012-06-08 · 2012-06-08
Transactions
1
First transaction's obligation
$6,967
Base + all options value (sum of deltas)
$6,967
Extent competed
NOT COMPETED UNDER SAP
Other than full & open authority
SAP NON-COMPETITION
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
424210 · DRUGS AND DRUGGISTS' SUNDRIES MERCHANT WHOLESALERS
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2012-06-08+$6,967= $6,967
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2012-06-08 | +$6,967 | $6,967 | HYZENTRA 20ML VIALS/ "CRITICAL FUNCTIONS" |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI S1RUKWWRYFL6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24126F0121 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $16,333 | FY2026 |
| 36C24226P0805 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $16,333 | FY2026 |
| 36C24026K1010 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,194,619,137 | FY2026 |
| 36C24026K1009 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,191,973,258 | FY2026 |
| 36C26226P1049 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $220,957 | FY2026 |
| 36C24026K1008 | VHA CHIEF LOGISTICS OFFICE (36C240) · 6505 · DRUGS AND BIOLOGICALS | $1,398,025,092 | FY2026 |
Other recipients under 6505 from 546-MIAMI (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24812P5514 | PROVEN PHARMACEUTICALS LLC | 546-MIAMI | $14,574 | FY2012 |
| VA24812P5013 | NXSTAGE MEDICAL, INC. | 546-MIAMI | $7,600 | FY2012 |
| VA24812F4842 | GRIFOLS BIOLOGICALS LLC | 546-MIAMI | $17,594 | FY2012 |
| VA24812F4551 | GRIFOLS BIOLOGICALS LLC | 546-MIAMI | $9,048 | FY2012 |
| VA24812F3815 | GRIFOLS BIOLOGICALS LLC | 546-MIAMI | $19,237 | FY2012 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24812P3822_3600_-NONE-_-NONE- · retrieved 2026-09-26.